1. Home
  2. CASI vs RADX Comparison

CASI vs RADX Comparison

Compare CASI & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • RADX
  • Stock Information
  • Founded
  • CASI 1991
  • RADX 2021
  • Country
  • CASI China
  • RADX Australia
  • Employees
  • CASI N/A
  • RADX N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • RADX
  • Sector
  • CASI Health Care
  • RADX
  • Exchange
  • CASI Nasdaq
  • RADX NYSE
  • Market Cap
  • CASI 29.7M
  • RADX 32.5M
  • IPO Year
  • CASI 1996
  • RADX N/A
  • Fundamental
  • Price
  • CASI $1.89
  • RADX $4.65
  • Analyst Decision
  • CASI Strong Buy
  • RADX Strong Buy
  • Analyst Count
  • CASI 1
  • RADX 2
  • Target Price
  • CASI $4.00
  • RADX $13.50
  • AVG Volume (30 Days)
  • CASI 7.1K
  • RADX 16.7K
  • Earning Date
  • CASI 05-16-2025
  • RADX 02-26-2025
  • Dividend Yield
  • CASI N/A
  • RADX N/A
  • EPS Growth
  • CASI N/A
  • RADX N/A
  • EPS
  • CASI N/A
  • RADX N/A
  • Revenue
  • CASI $31,368,000.00
  • RADX $204,609.00
  • Revenue This Year
  • CASI N/A
  • RADX N/A
  • Revenue Next Year
  • CASI N/A
  • RADX N/A
  • P/E Ratio
  • CASI N/A
  • RADX N/A
  • Revenue Growth
  • CASI 8.39
  • RADX N/A
  • 52 Week Low
  • CASI $1.64
  • RADX $3.50
  • 52 Week High
  • CASI $7.67
  • RADX $50.82
  • Technical
  • Relative Strength Index (RSI)
  • CASI 47.25
  • RADX N/A
  • Support Level
  • CASI $1.77
  • RADX N/A
  • Resistance Level
  • CASI $1.98
  • RADX N/A
  • Average True Range (ATR)
  • CASI 0.10
  • RADX 0.00
  • MACD
  • CASI 0.01
  • RADX 0.00
  • Stochastic Oscillator
  • CASI 54.55
  • RADX 0.00

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD

Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Share on Social Networks: